23andMe Keeps Snagging FDA Nods for Cancer Marker Tests

23andMe has won FDA clearance for a direct-to-consumer genetic test on a hereditary prostate cancer marker. The nod comes from nearly a year after the Sunnyvale, CA-based company announced it was going public through a special purpose acquisition corporation (SPAC) merger with VG Acquisition.